Science and Technology

Author Archive | xchem-editor

May 20, 2020

X-Chem Announces Licensing of a Drug Discovery Program to Otsuka

Waltham, Mass – May 20, 2020 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has licensed a drug discovery program from X-Chem.

Continue Reading
February 6, 2020

ALK-Abelló and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – February 5, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment […]

Continue Reading
January 13, 2020

ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery

New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chem’s proprietary DNA Encoded Library technology (DEX™) for the […]

Continue Reading
September 4, 2019

Maruho and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – September 4, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Maruho Co., Ltd. (Maruho) to discover lead compounds for novel and challenging targets […]

Continue Reading
May 27, 2019

Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry.

May 27, 2019|Molecules|Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry Inspired by the many reported successful applications of DNA-encoded chemical libraries in drug discovery projects with protein targets, we decided to apply this platform to nucleic acid targets. We used a 120-billion-compound set of 33 distinct DNA-encoded chemical libraries and affinity-mediated selection to […]

Continue Reading
January 4, 2019

X-Chem and Vertex Expand Existing Partnership

WALTHAM, Mass. – January 4, 2019 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).

Continue Reading
December 19, 2018

X-Chem Enters Strategic Collaboration with Bristol-Myers Squibb

WALTHAM, Mass. – December 18, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb.

Continue Reading
December 12, 2018

Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration

WALTHAM, Mass. – December 12, 2018 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications.

Continue Reading
June 29, 2018

X-Chem Announces Licensing of 50th Drug Discovery Program

WALTHAM, Mass. – July 26, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXTM) library drug discovery engine to the generation of novel small molecule therapeutics, today announced that it has licensed its 10th drug discovery program to date in 2018, bringing the total number of licensed programs […]

Continue Reading
April 24, 2018

X-Chem spin-off X-Biotix Therapeutics Completes $7 million Series A Financing

WALTHAM, Mass. April 24, 2018 – Small molecule drug discovery specialist X-Chem, Inc. (XChem) today announced that its spin-out company X-Biotix Therapeutics, Inc. (X-Biotix) has secured $7 million in a Series A financing from a group of private investors. X-Biotix, launched in 2017 out of X-Chem by Ramani Varanasi, Ph.D. and faculty members in the […]

Continue Reading